1.02
+0(+0.00%)
Currency In USD
| Previous Close | 1.02 |
| Open | 1.02 |
| Day High | 1.02 |
| Day Low | 0.98 |
| 52-Week High | 2.07 |
| 52-Week Low | 0.77 |
| Volume | 428,663 |
| Average Volume | 868,140 |
| Market Cap | 85.53M |
| PE | -3 |
| EPS | -0.34 |
| Moving Average 50 Days | 1.09 |
| Moving Average 200 Days | 1.18 |
| Change | 0 |
If you invested $1000 in Cardiol Therapeutics Inc. (CRDL) since IPO date, it would be worth $272.61 as of November 10, 2025 at a share price of $1.02. Whereas If you bought $1000 worth of Cardiol Therapeutics Inc. (CRDL) shares 5 years ago, it would be worth $451.63 as of November 10, 2025 at a share price of $1.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
Newsfile
Nov 05, 2025 12:45 PM GMT
The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
Newsfile
Oct 21, 2025 11:27 AM GMT
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027
Newsfile
Oct 17, 2025 8:34 PM GMT
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in